Compare Immunovant Inc. Common Stock (IMVT) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Raymond James Financial, Inc. — how do they compare? Immunovant Inc. Common Stock trades at $30.47 (market cap $6.25B), while Raymond James Financial, Inc. trades at $158.28 (market cap $30.51B). The key difference: Raymond James Financial, Inc. is far larger — about 4.9× Immunovant Inc. Common Stock's market cap, and Raymond James Financial, Inc. pays a 1.36% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 1 Days and Raymond James Financial, Inc. for 75 Days on average.
| IMVT | RJF | |
|---|---|---|
Market Cap | $6.25B | $30.51B |
Volume | 1,755,411 | 1,206,253 |
Sector | Health | Financials |
52-Week High | $44.96 | $181.18 |
52-Week Low | $17.03 | $140.89 |
Typical Hold Time | 1 Days | 75 Days |
Enterprise Value | $5.35B | $24.37B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Raymond James Financial (RJF) trades at $158.60, up 0.83% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 15.37% net margins and 18.48% ROE. Recent Q3 2026 results showed record revenues of $3.93 billion, beating expectations. The company continues dividend payments with a $0.54 quarterly payout declared for October 2026.
RJF presents a mixed outlook with strong fundamental performance offset by technical weakness. The 16% upside to consensus price target of $184.00 offers potential, but investors face headwinds from rising expenses and market volatility. The absence of sell ratings and consistent institutional interest supports the investment case, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
